Takura’s ownership interest: 65 %

The company works with allogenic stromal cells – i.e. cells from donors – for veterinary use. Horses are the prioritized target group and approximately 200 treatments have been carried out, with an 84% recovery rate.

The work of planning clinical studies is underway, and dogs are the next target group for treatment.

Business model

The business model is to produce cells which are used for treatments and to charge for each treatment. These treatments can be administered in own clinics or at external cooperation partners.